Prostate Cancer

Recently, there has been much controversy over whether patients with prostate cancer should be treated with bisphosphonates not only to decrease pain, but to prevent metastasis.

Recently, there has been much controversy over whether patients with prostate cancer should be treated with bisphosphonates not only to decrease pain, but to prevent metastasis.

NEW ORLEANS-In a phase II study, weekly docetaxel (Taxotere) significantly reduced bone pain and PSA levels in men with hormone-refractory prostate cancer, and these results led to enhanced quality of life. Lead investigator Tomasz Beer, MD, of Oregon Health Sciences University, reported the results at the 36th Annual Meeting of the American Society of Clinical Oncology (ASCO).

Clinical results demonstrate the potential of an investigational drug, exisulind (Aptosyn), to delay the need for androgen-deprivation therapy in men who have undergone prostatectomy and are at risk of prostate cancer recurrence. Detailed

SAN FRANCISCO-A new study supports the hypothesis that calcium consumption is associated with a greater risk of prostate cancer. June M. Chan, ScD, Department of Epidemiology, Harvard School of Public Health, presented the results at the 91st Annual Meeting of the American Association for Cancer Research (AACR).

NEW YORK-A small trial of trastuzumab (Herceptin) alone and with paclitaxel (Taxol) found that the combination was active against prostate cancer, but trastuzumab alone was not. The results were presented at the ASCO meeting by Michael J. Morris, MD, of Memorial Sloan-Kettering Cancer Center.

PHILADELPHIA-Significant benefit can be achieved from long-term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced prostate cancer.

Five-year follow-up data presented at the annual meeting of the American Urological Association (AUA) in Atlanta showed that the use of cryoablation as first-line treatment for prostate cancer can be as effective as radiation therapy. The five-center,

ATLANTA-For men with advanced or recurrent prostate cancer, 24 months of androgen deprivation accelerates bone loss, and these changes were significant at sites such as the forearm and hip, David M. Preston, MD (Maj., Medical Corps, U.S. Army), reported at the 95th Annual Meeting of the American Urological Association (AUA).

A multi-institutional study demonstrated that prostate cancer patients with aggressive tumors benefited from higher-than-standard doses of radiation. In the trial, 79% of 102 patients receiving radiation therapy for cancer confined to the prostate

TORONTO, Canada-A multicenter phase III trial involving more than 250 prostate cancer patients confirmed earlier trials demonstrating that abarelix, a GnRH antagonist, achieved more rapid reduction of testosterone to castrate levels than leuprolide acetate (Lupron) and bicalutamide (Casodex), but did not produce a testosterone surge and clinical flare.

ST. LOUIS-An automated technique for coregistering MRI or CT images with SPECT (single photo emission computed tomography) images has the potential to improve the accuracy of prostate cancer staging, according to research presented at the Society of Nuclear Medicine 47th Annual Meeting.

Current techniques for permanent prostate brachytherapy are associated with excellent biochemical control in patients with localized prostate cancer. Data now available confirm 5- to 10-year results with this treatment

AstraZeneca has announced the launch of a new website that will help keep researchers and physicians up to date on

Three-dimensional conformal radiation therapy (3D CRT) is more effective yet costs no more than conventional radiation therapy in the long-term treatment of prostate cancer, according to a study conducted at Fox Chase Cancer Center in

Physicians have long known that male hormones fuel prostate cancer growth. That’s why therapies that block the production of androgen-or testosterone-provide some of the most effective therapies for advanced prostate cancer. Certain drugs, for

ATLANTA-Many urologists treating men with prostate cancer are unaware that their patients are experiencing such disturbing treatment side effects as hot flashes, altered bowel habits, or weight change, according to the results of a national survey announced at the 95th Annual Meeting of the American Urological Association (AUA).

The US Food and Drug Administration has approved ALZA Corporation’s new drug application for a

AstraZeneca recently filed a supplemental new drug application with the US Food and Drug Administration (FDA) for a new indication for its oral hormonal medication bicalutamide (Casodex). The supplemental application asks the FDA to approve

FT. LAUDERDALE, Fla-Slight changes in the administration of salvage therapy after radical prostatectomy are among several revisions to the National Comprehensive Cancer Network (NCCN) Practice Guidelines for Prostate Cancer. The revised guidelines recommend radiotherapy for men with positive margins whose prostate-specific antigen (PSA) levels fail to fall to 0 ng/mL after surgery.

The results of an exploratory analysis published in the March 2000 issue of Urology suggest that prolonged combined androgen blockade (CAB) significantly increases survival in patients with advanced prostate cancer.

An estimated 180,400 new prostate cancer cases will be diagnosed in the United States this year, and many of these patients will be diagnosed and treated at community cancer centers.

BALTIMORE-The free prostate-specific antigen (PSA) test has proved as accurate in revealing prostate cancer risk in black men as in whites. “It also shows that many African-American men could be spared the expense and trauma of prostate biopsies,” Alan W. Partin, MD, PhD, co-leader of the research team, said in a news release from Johns Hopkins University where Dr. Partin is professor of urology.

CLEVELAND-A program at Travis Air Force Base in California is educating men about the purpose of prostate cancer screening by mailing brochures to the women who use medical services on the base. “This is a novel approach to going after the top men’s cancer,” said Maj. (Dr.) Darryl C. Hunter, medical director of the General Huyser Regional Cancer Center at Travis Air Force Base. He spoke at the 33rd annual meeting of the American Association for Cancer Education.

Hormonal therapy with the goserelin acetate implant (Zoladex) significantly increases overall survival rates in patients with locally advanced prostate cancer when administered at the onset of conventional external irradiation and continued for 3 years.